The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q2 2018 call → NO我们根据提供的财报电话会议记录,需要判断是否存在一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明显反驳了该疑虑。 首先,寻找疑虑。在电话会议中,分析师和公司管理层多次提到一些话题。例如,关于美国禽肉市场的疲软("weakness in the U.S. poultry market"),以及关税的影响。但这是否是一个长期存在的、公司特定的疑虑?管理层在回答中提到了全球多元化,但似乎没有明确说这是一个长期困扰公司的疑虑。 另一个可能的疑虑是关于自由现金流。管理层提到自由现金流低于预期,并解释了原因(库存增加等)。但这是否是一个长期疑虑?分析师Steve Tusa询问了现金流转换率,管理层表示未来应该能达到100%以上。这似乎是一个关注点,但可能不是长期疑虑。 更明显的可能是关于ASC 606会计变更的影响,但那是会计问题,不是公司特定疑虑。 再考虑:是否有分析师反复询问某个问题,表明这是一个长期疑虑?例如,关于美国禽肉市场,分析师Joel Tiss询问了蛋白质储存和关税影响,管理层回应了。但这是否是长期疑虑?可能不是。 另一个可能:关于AeroTech的订单强劲,但那是正面消息。 也许疑虑是关于公司能否维持增长?但似乎没有。 再读一遍:管理层提到"we continue to evaluate further opportunities to capture additional benefits as part of this program"关于重组计划。但那是计划。 也许疑虑是关于公司对单一市场的依赖?但管理层强调多元化。 实际上,在电话会议中,有一个明显的疑虑:关于美国禽肉市场的疲软,以及关税可能影响美国食品生产商。管理层承认了这一点,但表示全球多元化会缓解。这算是一个公司特定的疑虑吗?但分析师并没有反复追问,只是问了一次。 另一个可能的疑虑:关于自由现金流,分析师Steve Tusa问了很多关于现金流的问题,管理层解释了库存和应收账款。这似乎是一个关注点,但可能不是长期疑虑。 再考虑:是否有分析师提到"losses"?没有,公司是盈利的。 也许疑虑是关于公司能否实现其重组目标?但那是计划。 我认为最接近的疑虑可能是关于美国禽肉市场的疲软,但管理层并没有说这是一个长期疑虑,而是说这是当前市场状况。而且,本季度的订单强劲,蛋白质业务整体增长,所以实际证据反驳了这一点。 但问题要求"standing doubt"——一个长期存在的疑虑,而不是本季度新出现的。在电话会议中,是否有迹象表明分析师或管理层提到过去一直担心的事情?例如,关于公司对某一市场的依赖?没有明确。 另一个可能:关于公司能否维持高增长?但管理层给出了强劲的订单。 也许疑虑是关于公司能否将重组节省转化为利润?但那是未来。 再读一遍:在电话会议中,管理层提到"we continue to develop a strong pipeline of potential acquisition candidates"等,没有明显疑虑。 也许疑虑是关于公司能否应对关税?但那是宏观。 我认为没有明确的、公司特定的长期疑虑。分析师的问题都是针对当前季度的表现,没有提到长期担忧。 因此,答案应为NO。 但让我们再仔细检查:是否有分析师提到"the doubt that its losses will ever end"?没有,公司盈利。 "that its main product or model will find repeat demand"?没有。 "that its legacy business's decline will swamp everything else"?没有。 "that it depends too heavily on one customer, market, or financing source"?管理层提到多元化,但分析师没有特别质疑。 所以,没有明显的疑虑。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.